Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
Status:
Completed
Trial end date:
2020-04-29
Target enrollment:
Participant gender:
Summary
This is a research study to test an investigational drug (Not FDA approved), Apalutamide
given in combination with Leuprolide acetate (FDA approved) in men diagnosed with high-risk
prostate cancer who have already selected to have surgery to remove their prostate gland as
part of their treatment plan. The main purpose of this study is to determine how tumors make
androgens (male hormones), which makes these tumors more aggressive and resistant to hormonal
therapy and how a short period of treatment with Apalutamide and leuprolide acetate prior to
surgery can affect the production of these hormones in normal and malignant prostate tissue.